The European Commission updated its EIC Fund Investment Guidelines on 27 August, formalising something that had never existed before: direct EU equity investment in private defence companies. This is not a grant that converts to equity on milestones. It is a co-investment alongside private VCs, with the EIC Fund sitting on the cap table, subject to the same upside and the same illiquidity. Up to €30 million per company, drawn from the €100 million EIC STEP Scale Up Defence envelope. Applications close 28 October.
The structural importance is not the amount. It is the duration. Grants expire; equity does not. The EIC cannot exit without EU oversight, which means it is effectively a permanent anchor investor for companies building European defence capability -- interceptors, counter-drone systems, quantum sensing, AI for battlefield logistics. That durability is exactly what defence-hardware companies need from a backer and rarely get from VCs running five-year fund cycles. Europe is not just funding sovereign defence: it is building a permanent equity stake in it.
Against that backdrop, Pasqal's Nasdaq debut on 28 August looked like a different kind of threshold: a French quantum computing company -- co-founded by 2022 Nobel laureate Alain Aspect -- went public via SPAC merger with Bleichroeder Acquisition Corp. II, landing €309 million in cash at closing. Shares rose 95 per cent on debut. Pasqal is the first major European deep-tech company to list on a US exchange without relocating to the US, and without making a US headquarters a condition of the listing. For European founders who assumed the only path to public-market liquidity required an Atlantic crossing, Pasqal's debut is a proof of concept.
Grant World
Two Days to the EIC Accelerator; Eight Weeks to the Pathfinder
Two deadlines expire this week. After that, a cluster of October calls that most founders have not yet opened.
⚠️ EIC Accelerator -- Batch 5 full proposals
Add toGrok
· 2 Sep 2026 · Up to €2.5M grant + up to €15M equity · For companies holding a short-application invitation. If you received one, your full proposal is due Wednesday. No invitation means no access this batch.
EIC STEP Scale Up (civilian)
· 9 Sep 2026 · EU equity co-investment into rounds of €50M+ · Sectors: AI, deeptech, cleantech, digital infrastructure, biotech · Eligibility: EU, EEA, and UK companies under 500 employees · If you have investor pre-commitments and a round that can absorb an institutional equity anchor, this is the most capital-efficient instrument in the stack.
Horizon Europe -- Cancer Mission
· 15 Sep 2026 · Multi-million-euro grants for cancer prevention, detection, and treatment research.
EIC Transition
· 16 Sep 2026 · Up to €2.5M · No equity taken · For teams with prior Horizon Europe (Pillar 2), EIC Pathfinder, ERC Proof of Concept, or Research Infrastructures funding -- bridges validated research to commercial product.
Mission Ocean (Horizon Europe)
· 23 Sep 2026 · Blue economy and ocean ecosystem restoration calls.
EIC Pathfinder Challenges
· 28 Oct 2026 · €96M total · Three challenges: Advanced Materials for Miniaturised Energy Harvesting, Biotechnology for Healthy Ageing, and
DeepRAP
(trustworthy cognitive AI systems) · €32M per challenge · Open to 1-2 member consortia including UK applicants · This is the most underused instrument in the EIC portfolio: Pathfinder funds science too early for Accelerator and too visionary for most private labs.
EIC STEP Scale Up Defence
· 28 Oct 2026 · €100M · Up to €30M equity per company · The first call in EU history to invest direct equity in defence companies · Open to EU, EEA, and Ukraine-registered companies.
Who Got Funded
Science Founders, French Capital, and a Nasdaq Debut
Pasqal -- Paris, France · €309M (Nasdaq listing via SPAC) · Public · Quantum computing · Bleichroeder Acquisition Corp. II
The first major European quantum company to go public on a US exchange without relocating. Founded 2019 on research that earned the 2022 Nobel Prize in Physics; Alain Aspect chairs the combined company. Shares rose 95 per cent on debut (28 Aug). Customers include Saudi Aramco and LG Electronics.
Lupin Dental -- Montpellier, France · €15M · Series A · Dental robotics · Fynveur (lead, Invus-advised), Bpifrance (loan)
The Lupin Robotic System automates minimally invasive veneer preparation, a procedure requiring sub-millimetre precision across an entire tooth surface. Received UKCA certification in June 2026; EU CE mark pending. Fynveur's long-hold mandate fits a med-tech commercialisation cycle that most five-year VC funds cannot sustain.
Revier Therapeutics -- Heidelberg, Germany · €6M · Seed · Biotech / cardiometabolic disease · KHAN Technology Transfer Fund II (lead), HTGF, VORNvc
Launched from stealth (25 Aug) to pioneer Class IIa HDAC inhibitors for cardiometabolic disease -- a target class largely overlooked by pharma. HTGF's participation alongside a university transfer fund is a signal of scientific credibility; the KHAN model of spinning out clinical-stage chemistry into standalone companies is accelerating.
Clementine -- Maastricht, Netherlands · €1.7M · Seed · AI-powered hearing care · Healthy.Capital (lead)
An AI platform running the patient-acquisition and booking layer for hearing clinics, including a round-the-clock voice agent. Founded 2024; already integrated with multi-location chains. At €1.7M, the smallest institutional cheque of the week -- in a market whose digital infrastructure is a decade behind its patient volume.
Ponda -- Bristol, United Kingdom · €1.6M · Community round (crowdfunding) · Biomaterials / sustainable textiles
Closed at nearly seven times the minimum target. BioPuff -- insulation made from bulrushes grown on restored UK peatland -- is scaling into fashion supply chains. A crowdfunding round that beats its minimum by 7x signals consumer-side conviction that institutional investors will eventually price in.
Four of five rounds this week involved scientific founders or biotech-adjacent problems: quantum computing, dental robotics, HDAC inhibitors, wetland fibre engineering. European venture this week was overwhelmingly a bet on science, not distribution.
Where EU Money Is Flowing
Three Structural Shifts
Government equity is replacing grants as the primary instrument for strategic sectors. The EIC's updated Investment Guidelines (27 August) are the clearest signal yet: for deep-tech, defence, and quantum, the EU is moving from grantor to shareholder. EIB venture debt in Oceanloop's round last week, EIC STEP equity in earlier batches, and now direct defence equity -- the development finance model is converging on the cap table. For private co-investors, the EU's presence as an anchor reduces early-stage valuation risk and extends effective runway beyond what a private lead can offer alone.
France is pulling away as Europe's deep-tech production hub. Pasqal (Paris, Nasdaq-listed), Lupin Dental (Montpellier, €15M Series A), the E2D Franco-German €500M defence fund, and Paris capturing 77 per cent of French deep-tech capital in 2025 -- the pattern is consistent. Not every EU country is building at the same pace. France's combination of CNRS spinout culture, Bpifrance co-investment discipline, and Grandes Écoles talent is compounding into a structural advantage. The next generation of European deep-tech champions is disproportionately likely to be French.
Life-science technology transfer funds are becoming cap-table participants, not just facilitators. The KHAN Technology Transfer Fund II leading Revier's seed round -- writing an equity cheque, not a grant -- is part of a broader shift: university tech-transfer offices and their associated funds are moving from licensing and introductions to direct investment. HTGF's co-investment alongside KHAN signals that these early cheques are credible enough to attract Germany's premier seed investor as a follower rather than the lead. The supply of science-stage equity is increasing faster than most founders realise.
One Move
If You Have an EIC Accelerator Invitation, Wednesday Is Your Last Window
The EIC Accelerator Batch 5 full proposal deadline is September 2 -- 48 hours from today. This is not a general application; it is exclusive to companies that received a short-application invitation. If you received one and have not submitted, there is no grace period and no next batch before October. Missing Wednesday means waiting two months.
The full proposal requires a 20-page submission (the EIC cut this from 50 pages in the 2026 work programme), a business plan video, and supporting financials. The award is up to €2.5M in non-dilutive grant funding plus up to €15M in EIC Fund equity investment, subject to due diligence. Submit through the EIC Portal under your active application. If you are in this window and have the invitation, block Wednesday morning and submit.
The weekly briefing
Funding calls, VC news and key deadlines. Free to read; unsubscribe anytime.
